Latest Advances in Tuberculosis Diagnosis, Prevention, and Treatment Offer Hope for Global Control
Tuberculosis (TB) remains one of the world’s deadliest infectious diseases, but recent breakthroughs in diagnostics, prevention strategies, and treatment approaches are offering renewed hope for controlling its spread. Researchers at the University of Washington and the Fred Hutchinson Cancer Center are at the forefront of these efforts, focusing on innovative solutions to address the persistent challenges posed by this global health threat.
Improved TB Diagnostics: A New Tongue Swab Test
A significant advancement in TB diagnosis is a new tongue swab test, developed through research at the University of Washington. This non-invasive test, endorsed by the World Health Organization (WHO) earlier this month, will help identify individuals with potential signs of TB who require further diagnostic evaluation. According to Dr. Adrienne Shapiro, this easier diagnostic approach will increase access to testing, particularly for those living with HIV.
Uncovering Asymptomatic TB Cases
Research has revealed a surprising finding: up to 80% of TB cases may be asymptomatic. This discovery, stemming from a COVID-19 Prevention Network trial led by researchers at Fred Hutch in South Africa, is prompting a major shift in understanding the progression of TB infection. The trial initially focused on mRNA SARS-CoV-2 vaccines and boosters, but researchers noticed a high incidence of TB among participants, even though it wasn’t the study’s primary focus. A subsequent TB sub-study, involving 6,000 participants, allowed researchers to collect valuable data and search for biomarkers that could identify individuals at high risk of developing TB disease.
The Search for TB Biomarkers
Researchers are now working to identify biomarkers that could be used in an easy-to-administer test to detect individuals at high risk of TB. This would allow for earlier intervention and treatment, potentially preventing the development of symptomatic disease. The team is analyzing differences between individuals who test negative for TB, those who are positive but asymptomatic, those with TB symptoms, and those with X-ray signs of TB but negative sputum tests.
Addressing Drug Interactions in HIV and TB Treatment
A challenge in TB and HIV treatment is potential drug interactions, particularly with long-acting formulations of HIV pre-exposure prophylaxis (PrEP). Dr. Shapiro and the Seattle Vaccine Trials Unit are collaborating with pharmaceutical companies to conduct drug-drug interaction studies to determine if PrEP can be safely administered alongside TB treatment or preventative therapy, or if dosage adjustments are necessary. The goal is to ensure that effective HIV prevention strategies are accessible in regions where TB is also prevalent.
New Approaches to TB Treatment and Immune Response
Research suggests that much of the damage caused by TB disease stems from the body’s own immune response, rather than the bacterium itself. Scientists are exploring ways to modulate the immune system to reduce this damage. One promising avenue involves impeding the recruitment of neutrophils, a type of white blood cell, during TB infection. Preclinical studies in animal models have shown that this strategy can lead to healing with less scarring. Further research suggests that early neutrophil responses play a key role in TB pathology.
Increased Investment in TB Research
There has been a significant increase in investment in TB research in recent years, including funding from the National Institutes of Health (NIH) and the Gates Foundation. This renewed commitment is driving momentum in the field and accelerating the development of new tools and strategies to combat TB. Dr. Fiore-Gartland noted this shift in the last five years.
Key Takeaways
- A new, non-invasive tongue swab test for TB has been endorsed by the WHO, promising to improve access to diagnosis.
- Research indicates that a large proportion of TB cases are asymptomatic, highlighting the need for proactive screening and biomarker development.
- Studies are underway to address potential drug interactions between long-acting PrEP and TB treatments.
- Modulating the immune response, particularly by targeting neutrophils, may reduce lung damage caused by TB.
- Increased investment in TB research is fueling innovation and progress towards global control.